Etelinterakcios farmakokinetikai vizsgalatok helye es jelentosege a gyogyszerfejleszteben Teofillin retard, nifedipin retard es buspiron tablettak etelinterakcios vizsgalata

Translated title of the contribution: Role of food interaction pharmacokenitic studies in drug development. Food interaction studies of theophylline and nifedipine retard, and buspirone tablets

Sándor Drabant, I. Klebovich, Béla Gachályi, Gábor Renczes, C. Farsang

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Due to several mechanism, meals may modify the pharmacokinetics of drug products, thereby eliciting to clinically significant food interaction. Food interactions with the drug substance and with the drug formulation should be distinguished. Food interaction of different drug products containing the same active ingredient can be various depending on the pharmaceutical formulation technology. Particularly, in the case of modified release products, the food/formulation interaction can play an important role in the development of food interaction. Well known example, that bioavailability of theophylline can be influenced in different way (either increased, decreased or unchanged) by concomitant intake of food in the case of different sustained release products. The role and methods of food interaction studies in the different kinds of drug development (new chemical entity, modified release products, generics) are reviewed. Prediction of food effect response on the basis of the physicochemical and pharmacokinetic characteristics of the drug molecule or formulations is discussed. The results of three food interaction studies carried out the products of EGIS Pharmaceuticals Ltd. are also reviewed. The pharmacokinetic parameters of theophyllin 400 mg retard tablet were practically the same in both fasting condition and administration after consumption of a high fat containing standard breakfast. The ingestion of a high fat containing breakfast, increased the AUC of nifedipine from 259.0 ± 101.2 ng h/ml to 326.7 ± 122.5 ng h/ml and C(max) from 34.5 ± 15.9 ng/ml to 74.3 ± 23.9 ng/ml in case of nifedipine 20 mg retard tablet, in agreement with the data of literature. The statistical evaluation indicated significant differences between the pharmacokinetic parameters in the case of two administrations (before and after meal). The effect of a high fat containing breakfast for a generic version of buspiron 10 mg tablet and the bioequivalence after food consumption were studied in a single-dose, three- way (test and reference products administered after consumption of standard breakfast, as well as test product in fasting condition), cross-over, food effect bioequivalence study. According to the results, the test product - which, in a former study proved to be bioequivalent with the reference product in fasting state - is bioequivalent with the reference product under feeding conditions and the food intake influenced the pharmacokinetics of the test tablets.

Original languageHungarian
Pages (from-to)294-306
Number of pages13
JournalActa Pharmaceutica Hungarica
Volume68
Issue number5
Publication statusPublished - Sep 1998

Fingerprint

Food-Drug Interactions
Buspirone
Nifedipine
Theophylline
Tablets
Breakfast
Pharmacokinetics
Pharmaceutical Preparations
Fasting
Therapeutic Equivalency
Drug Compounding
Eating
Fats
Food
Meals
Pharmaceutical Technology
Biological Availability
Area Under Curve

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

@article{465a0231363040479a25d7c9987f3524,
title = "Etelinterakcios farmakokinetikai vizsgalatok helye es jelentosege a gyogyszerfejleszteben Teofillin retard, nifedipin retard es buspiron tablettak etelinterakcios vizsgalata",
abstract = "Due to several mechanism, meals may modify the pharmacokinetics of drug products, thereby eliciting to clinically significant food interaction. Food interactions with the drug substance and with the drug formulation should be distinguished. Food interaction of different drug products containing the same active ingredient can be various depending on the pharmaceutical formulation technology. Particularly, in the case of modified release products, the food/formulation interaction can play an important role in the development of food interaction. Well known example, that bioavailability of theophylline can be influenced in different way (either increased, decreased or unchanged) by concomitant intake of food in the case of different sustained release products. The role and methods of food interaction studies in the different kinds of drug development (new chemical entity, modified release products, generics) are reviewed. Prediction of food effect response on the basis of the physicochemical and pharmacokinetic characteristics of the drug molecule or formulations is discussed. The results of three food interaction studies carried out the products of EGIS Pharmaceuticals Ltd. are also reviewed. The pharmacokinetic parameters of theophyllin 400 mg retard tablet were practically the same in both fasting condition and administration after consumption of a high fat containing standard breakfast. The ingestion of a high fat containing breakfast, increased the AUC of nifedipine from 259.0 ± 101.2 ng h/ml to 326.7 ± 122.5 ng h/ml and C(max) from 34.5 ± 15.9 ng/ml to 74.3 ± 23.9 ng/ml in case of nifedipine 20 mg retard tablet, in agreement with the data of literature. The statistical evaluation indicated significant differences between the pharmacokinetic parameters in the case of two administrations (before and after meal). The effect of a high fat containing breakfast for a generic version of buspiron 10 mg tablet and the bioequivalence after food consumption were studied in a single-dose, three- way (test and reference products administered after consumption of standard breakfast, as well as test product in fasting condition), cross-over, food effect bioequivalence study. According to the results, the test product - which, in a former study proved to be bioequivalent with the reference product in fasting state - is bioequivalent with the reference product under feeding conditions and the food intake influenced the pharmacokinetics of the test tablets.",
author = "S{\'a}ndor Drabant and I. Klebovich and B{\'e}la Gach{\'a}lyi and G{\'a}bor Renczes and C. Farsang",
year = "1998",
month = "9",
language = "Hungarian",
volume = "68",
pages = "294--306",
journal = "Acta Pharmaceutica Hungarica",
issn = "0001-6659",
publisher = "Magyar Gyogyszereszeti Tarsasag",
number = "5",

}

TY - JOUR

T1 - Etelinterakcios farmakokinetikai vizsgalatok helye es jelentosege a gyogyszerfejleszteben Teofillin retard, nifedipin retard es buspiron tablettak etelinterakcios vizsgalata

AU - Drabant, Sándor

AU - Klebovich, I.

AU - Gachályi, Béla

AU - Renczes, Gábor

AU - Farsang, C.

PY - 1998/9

Y1 - 1998/9

N2 - Due to several mechanism, meals may modify the pharmacokinetics of drug products, thereby eliciting to clinically significant food interaction. Food interactions with the drug substance and with the drug formulation should be distinguished. Food interaction of different drug products containing the same active ingredient can be various depending on the pharmaceutical formulation technology. Particularly, in the case of modified release products, the food/formulation interaction can play an important role in the development of food interaction. Well known example, that bioavailability of theophylline can be influenced in different way (either increased, decreased or unchanged) by concomitant intake of food in the case of different sustained release products. The role and methods of food interaction studies in the different kinds of drug development (new chemical entity, modified release products, generics) are reviewed. Prediction of food effect response on the basis of the physicochemical and pharmacokinetic characteristics of the drug molecule or formulations is discussed. The results of three food interaction studies carried out the products of EGIS Pharmaceuticals Ltd. are also reviewed. The pharmacokinetic parameters of theophyllin 400 mg retard tablet were practically the same in both fasting condition and administration after consumption of a high fat containing standard breakfast. The ingestion of a high fat containing breakfast, increased the AUC of nifedipine from 259.0 ± 101.2 ng h/ml to 326.7 ± 122.5 ng h/ml and C(max) from 34.5 ± 15.9 ng/ml to 74.3 ± 23.9 ng/ml in case of nifedipine 20 mg retard tablet, in agreement with the data of literature. The statistical evaluation indicated significant differences between the pharmacokinetic parameters in the case of two administrations (before and after meal). The effect of a high fat containing breakfast for a generic version of buspiron 10 mg tablet and the bioequivalence after food consumption were studied in a single-dose, three- way (test and reference products administered after consumption of standard breakfast, as well as test product in fasting condition), cross-over, food effect bioequivalence study. According to the results, the test product - which, in a former study proved to be bioequivalent with the reference product in fasting state - is bioequivalent with the reference product under feeding conditions and the food intake influenced the pharmacokinetics of the test tablets.

AB - Due to several mechanism, meals may modify the pharmacokinetics of drug products, thereby eliciting to clinically significant food interaction. Food interactions with the drug substance and with the drug formulation should be distinguished. Food interaction of different drug products containing the same active ingredient can be various depending on the pharmaceutical formulation technology. Particularly, in the case of modified release products, the food/formulation interaction can play an important role in the development of food interaction. Well known example, that bioavailability of theophylline can be influenced in different way (either increased, decreased or unchanged) by concomitant intake of food in the case of different sustained release products. The role and methods of food interaction studies in the different kinds of drug development (new chemical entity, modified release products, generics) are reviewed. Prediction of food effect response on the basis of the physicochemical and pharmacokinetic characteristics of the drug molecule or formulations is discussed. The results of three food interaction studies carried out the products of EGIS Pharmaceuticals Ltd. are also reviewed. The pharmacokinetic parameters of theophyllin 400 mg retard tablet were practically the same in both fasting condition and administration after consumption of a high fat containing standard breakfast. The ingestion of a high fat containing breakfast, increased the AUC of nifedipine from 259.0 ± 101.2 ng h/ml to 326.7 ± 122.5 ng h/ml and C(max) from 34.5 ± 15.9 ng/ml to 74.3 ± 23.9 ng/ml in case of nifedipine 20 mg retard tablet, in agreement with the data of literature. The statistical evaluation indicated significant differences between the pharmacokinetic parameters in the case of two administrations (before and after meal). The effect of a high fat containing breakfast for a generic version of buspiron 10 mg tablet and the bioequivalence after food consumption were studied in a single-dose, three- way (test and reference products administered after consumption of standard breakfast, as well as test product in fasting condition), cross-over, food effect bioequivalence study. According to the results, the test product - which, in a former study proved to be bioequivalent with the reference product in fasting state - is bioequivalent with the reference product under feeding conditions and the food intake influenced the pharmacokinetics of the test tablets.

UR - http://www.scopus.com/inward/record.url?scp=0032161964&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032161964&partnerID=8YFLogxK

M3 - Article

C2 - 9805816

AN - SCOPUS:0032161964

VL - 68

SP - 294

EP - 306

JO - Acta Pharmaceutica Hungarica

JF - Acta Pharmaceutica Hungarica

SN - 0001-6659

IS - 5

ER -